The multi-center clinical trial has enrolled 258 healthy participants between the ages of 18 and 50 years, making this study the largest Phase I study conducted to date by Vaxxas with its HD-MAP ...

FORWARD-53 is an ongoing Phase 2 open-label trial of WVE-N531. Muscle biopsies are taken after 24 and 48 weeks of dosing. The ...

According to the terms of the deal, Blackstone will acquire a 60 percent stake while CMIC HD will retain the remaining 40 percent stake in the company.

Q4 2024 Earnings Call Transcript March 4, 2025 Wave Life Sciences Ltd. beats earnings expectations. Reported EPS is $0.17, expectations were $-0.17. Operator: Good morning and welcome to the Wave Life ...

Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort Multi-dosing ongoing in 200 mg cohort of RestorAATion-2 ...

A 14-year study tracking NfL levels in people with the HD gene shows this tiny protein can signal disease progression many ...

Prostate cancer remains one of the most commonly diagnosed cancersworldwide, with 1.4 million new cases and over 375,000 ...

Jeffrey Dayno; President, Chief Executive Officer, Director; Harmony Biosciences Holdings Inc Jeffrey Dierks; Chief Commercial Officer; Harmony Biosciences Holdings Inc Kumar Budur; EVP and Chief ...

Harmony Biosciences Holdings Inc (HRMY) reports robust financial performance and strategic progress, despite facing ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...